Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703

Impact of posttransplant cyclophosphamide-based GVHD prophylaxis in patients 70 years and older: an update from BMT CTN 1703

Abstract: Allogeneic hematopoietic cell transplant (allo-HCT) is underutilized in adults aged ≥70 years. Morbidity, often driven by graft-versus-host disease (GVHD), is considered a major barrier to its use. The BMT CTN 1703 trial (ClinicalTrials.gov identifier: NCT03959241) randomly assigned adults...

Full description

Saved in:
Bibliographic Details
Main Authors: Sameem Abedin, Michael J. Martens, Javier Bolaños-Meade, Monzr M. Al Malki, Qinghua Lian, Lyndsey Runaas, Hany Elmariah, Mahasweta Gooptu, Karilyn T. Larkin, Brian C. Shaffer, Alison W. Loren, Melhem Solh, Amin M. Alousi, Omer H. Jamy, Miguel-Angel Perales, Andrew Rezvani, Ami Bhatt, Najla El Jurdi, Janny M. Yao, Kristy Applegate, Leslie S. Kean, Yvonne A. Efebera, Ran Reshef, William Clark, Eric Leifer, Wael Saber, Mary M. Horowitz, Richard J. Jones, Shernan G. Holtan, Mehdi Hamadani
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:Blood Advances
Online Access:http://www.sciencedirect.com/science/article/pii/S2473952925002599
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2473952925002599

Similar Items